,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'destiny-breast04']
the results of destiny-breast04 published in t-dxd in previously treated her2-low abc hr+ cohort pfs; 10.1 vs 5.4 mos,hr:0.51 os; 23.9 vs 17.5 mos,hr:0.64
all pts pfs; 9.9 vs 5.1 mos,hr:0.5 os; 23.4 vs 16.8 mos,hr:0.64 #asco22 
Medical Oncologist